Agilent (A) announced its PD-L1 IHC 22C3 pharmDx assay has received European IVDR certification for the use as a Companion Diagnostic to aid in the identification of gastric or gastroesophageal Junction adenocarcinoma patients who may be eligible for treatment with Keytruda. PD-L1 IHC 22C3 pharmDx is approved for exclusive use with the Agilent Autostainer Link 48 advanced staining solution.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on A: